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Despite  the  licensure  of  the  pneumococcal  conjugate  vaccine  (PCV)  in  the US  and  other  Western  countries
for  over  14  years,  as  of  September  2014  only  4  South  Asian  countries  were  using  PCV  in their  universal
immunization  program.  To  generate  momentum  toward  addressing  this  issue  a “South  Asia  symposium
on  pneumococcal  disease  and  the  promise  of  vaccines”  was  organized  just  prior  to  the  9th interna-
tional  symposium  on pneumococci  and pneumococcal  diseases  held  in India  recently.  Leading  scientists,
program  managers,  and  decision  makers  including  ministry  ofﬁcials  from  the  region  participated  in
the  meeting.  The  participants  discussed  available  data  on  pneumococcal  disease  burden  in South  Asia,neumococcal conjugate vaccines
mmunization programs
outh Asia
ndia
neumococcal disease burden
surveillance  methods,  efﬁcacy  and  safety  of  pneumococcal  conjugate  vaccines  (PCV),  the status  of  PCV
introduction,  programmatic  challenges  in  introducing  PCV  and  available  data  on  the  impact  of  PCV  in
South  Asia  and globally.  There  was  a  strong  consensus  that  available  data  on  disease  burden  and  the
global  experience  with  PCV  justiﬁed  the  introduction  PCV  in  all Asian  countries  in  order  to  accelerate  the
gains in  child  survival  in the  region.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
The ninth international symposium on pneumococci and pneu-
ococcal diseases (ISPPD-9) was held in Hyderabad, India from
arch 9 to 13, 2014. The ISPPD has been convening eminent
cientists from around the world to discuss the latest scientiﬁc
evelopments in the ﬁeld of pneumococcal diseases and preven-
ion strategies biennially since 1998. Previous ISPPD meetings paid
pecial attention to the role of pneumococcal conjugates vaccines
n disease prevention, emerging data on serotype replacement
ost-immunization, and the importance of continuous disease
urveillance both before and after pneumococcal vaccine introduc-
ion [1–3]. ISPPD-9 reviewed advancements made in these areas,
nd also examined evidence that could inform the development
f policies and programs relating to pneumococcal disease, and
ccelerate access to pneumococcal vaccines in the world’s poorest
ountries.
∗ Corresponding author at: Department of International Health, Johns Hopkins
loomberg School of Public Health, 415 N Washington St 4th Floor, Baltimore, MD
1231, USA. Tel.: +1 410 955 6931; fax: +1 410 955 2010.
E-mail address: msantosham@jhu.edu (M.  Santosham).
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.071
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
ISPPD-9 also marked the ﬁrst time, the conference was  held in
Asia. It provided an extraordinary opportunity to foster collabo-
rations, promote knowledge sharing and examine topics ranging
from the epidemiology of and diagnostics for pneumococcal disease
to the development of disease control policies in low- and middle-
income countries (LMICs). To this aim, a satellite meeting – the
South Asia symposium on pneumococcal disease and the promise
of vaccines – was held in conjunction with ISPPD on March 9, 2014.
Leading scientists, program implementers, and decision-makers
including ofﬁcials of Ministries of Health from Asian countries con-
vened to examine and review the available scientiﬁc data and share
policy and programmatic considerations for pneumococcal conju-
gate vaccine (PCV) introduction. The purpose of the symposium
was to accelerate the introduction and uptake of PCV in the region,
speciﬁcally in countries like India facing the highest burden of
pneumococcal disease.
The co-chairs of the South Asia symposium, Dr. Narendra Arora
and Dr. Mathuram Santosham opened the meeting by remarking
on the timeliness of the gathering, underscoring the need for tack-
ling pneumonia as a top public health priority and highlighting
the promising role of prevention through vaccination in reducing
pneumonia-related childhood morbidity and mortality.
The key-note speaker, Dr. Rakesh Kumar, Joint Secretary (Repro-
ductive & Child Health Programme) to the Government of India,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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inistry of Health and Family Welfare shared India’s progress
oward improving child and maternal health, and reviewed the
teps India had taken to reinvigorate its commitment toward
chieving the millennium development goals (MDGs). Speciﬁcally,
he national government had increased allocations from 1.36% to
.87% of the GDP to the health sector and implemented policies to
cale-up high-impact interventions for newborn and child survival,
ncluding key interventions to reduce pneumonia-related deaths
n India [4,5]. Speciﬁcally, Dr. Kumar acknowledged existing health
ystem barriers – such as, the irregular supply of essential antibi-
tics, inadequate capacity of the public health workforce, and the
ailure to implement policies at the subnational level – that have
tymied progress toward reducing pneumonia-related deaths [4].
n his concluding slide, Dr. Kumar reﬂected on the policy decision
o introduce PCV currently facing the country [4].
This query set the stage for the symposium’s agenda of exam-
ning available evidence to facilitate discussions and debate to
dentify barriers to PCV introduction and lessons learnt from other
ountries. This article presents a summary of these deliberations
nd the conclusions of the symposium according to the following
hematic areas:
. Epidemiology, disease surveillance methods, and estimates of
pneumococcal disease burden globally and in South Asia.
. Safety, efﬁcacy, and the impact of PCV.
. Policy and programmatic considerations to support country-
level decision-making for PCV introduction.
. A call to action to leverage the promising role of PCV in preven-
ting pneumococcal disease burden in the region.
. Burden of pneumococcal disease in South Asia and
hallenges of pneumococcal disease surveillance
The ﬁrst panel reviewed the epidemiology of the pneumococcal
isease globally and in South Asia and highlighted the successes
nd challenges of disease surveillance in Asia. Dr. Thomas Cherian
resented World Health Organization’s (WHO) unofﬁcial estimates
rom 2008, which reported approximately 100,000 deaths from
neumococcal pneumonia and 13,000 deaths from pneumococcal
eningitis in South Asia based on data from Bangladesh, Bhutan,
ndia, Maldives, Nepal, Pakistan and Sri Lanka [6]. Dr. Cherian
lso described the challenges of establishing Streptococcus pneu-
oniae (Spn or pneumococcus) etiology and how it had limited the
irect estimation of the pneumococcal disease burden. In particu-
ar, evidence supported that surveillance of laboratory conﬁrmed
ulture positives of Spn disease represented only the “tip of the
ceberg” because a vast majority of pneumonia cases are not eas-
ly diagnosed [6,7]. Experts at the meeting generally agreed that
he previously held belief of low pneumococcal disease burden in
sia was likely due to diagnostic factors like lowered sensitivity of
ulture techniques, antibiotic use before diagnostic work up, and
elay in processing of specimens, which limited the availability
f national estimates on disease burden. When newer diagnostic
echniques were used, the rates of disease were similar to other
eveloping regions of the world such as Africa [8]. For example,
ates of invasive pneumococcal disease (IPD) detection were con-
istently higher in studies which used antigen detection techniques
ike latex agglutination and immunochromatography, or molecular
ssays like PCR in conjunction with culture especially for detection
f pathogens in the cerebrospinal ﬂuid [9,10].
Furthermore, experts acknowledged the differences in the
nnual incidence of invasive pneumococcal disease (IPD) among
ve year olds living in countries sharing similar socio-economic and
ortality proﬁles in the region. They concluded, the incidence of
PD among under ﬁve year olds – ranged from approximately 204 (2016) 2622–2626 2623
per 100,000 in Sri Lanka to 3058 per 100,000 in Bangladesh and
that these differences were likely representative of differences in
the diagnostic methodologies and surveillance methods that were
used [11].
Based on the available epidemiological data reviewed at the
symposium, experts at the meeting agreed there was sufﬁcient evi-
dence at the time to conclude the epidemiology of S. pneumoniae
in Asian countries was  comparable to that seen in other countries
with similar socio-economic and mortality proﬁles prior to vac-
cine introduction. Therefore, in order to address the high burden of
pneumococcal disease in region, particularly in India, Pakistan and
Bangladesh, there was strong consensus to improve surveillance
for invasive pneumococcal disease by providing adequate ﬁnancial
and technical support by global development partners. Although
speciﬁcally not discussed, alternative and innovative ﬁnancing
mechanisms that have successfully expanding the ﬁscal space for
health should be considered as potential tools for ﬁnancing new
vaccine introduction [12].
Dr. Pushpa Wijesinghe synthesized the successes and challenges
of IPD surveillance from the experiences of the WHO-supported
surveillance networks established in South and Southeast Asian
countries. Establishing in-country sentinel surveillance networks
had several advantages, including the generation of local and
regional data on pneumococcal disease incidence and prevalence,
as well as, bringing transparency to decision making processes at
the National Immunization Technical Advisory Groups (NITAGs)
in different countries [11]. The NITAGs in Bangladesh and Nepal
selected PCV10 over PCV13 for national introduction in 2015. In
making that decision, they took into account many factors including
serotype coverage, presentation of the vaccine, cost of the vaccine,
and cold chain issues etcetera. Similarly, regional data generated
through these surveillance networks informed Myanmar’s deci-
sion to introduce PCV10 despite lacking country-based surveillance
mechanisms.
Evidence of IPD serotype distribution through surveillance
networks also addressed the historic concerns about the serotype
distribution in Asia, where questions about regional serotype cov-
erage of the currently available pneumococcal vaccines have been
raised. Available evidence on serotype prevalence for pneumo-
cocci in the region from India, Nepal, Bangladesh and Sri Lanka
demonstrated that PCV10 covers approximately 70% and PCV13
covers approximately 74% of the serotypes which cause IPD [13].
These data are important for countries like India and Sri Lanka
that are still determining whether to introduce PCV in their
national immunization programs, as well as for countries conduct-
ing evaluations to assess the impact of PCV on both vaccine and
non-vaccine type pneumococcal serotypes. It was also reported
that IPD surveillance networks enhanced the capacity of country-
led surveillance efforts and informed policy changes in certain
countries. For example, India and Bangladesh integrated Acute
Meningitis/Encephalitis Surveillance (AMES) with their existing
polio and measles surveillance networks [11]. In addition, in Sri
Lanka, data on antibiotic sensitivity gathered from pneumococcal
surveillance informed changes in the antibiotic prescription policy
[11].
Despite these successes, several concerns about the sustain-
ability of these WHO-supported networks were raised, speciﬁcally,
the dependence on external funding of ongoing surveillance
activities, the lack of country leadership and the immediate need
for establishing adequate surveillance systems in order to monitor
serotype replacement in countries post-vaccine introduction [11].
Other challenges that were discussed related to diagnosis and data
quality, for example, the lack of standardization of surveillance
practices and data management, poor quality of existing culture
techniques, limited access to newer higher sensitivity diagnostics,
extensive use of antibiotics prior to obtaining diagnostic specimen,
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nd difﬁculty in the timely transfer of specimens to reference
aboratories [11].
Dr. Gungaa Surenkhand highlighted the challenges of surveil-
ance for invasive bacterial diseases (IBD) caused by pneumococci
n Mongolia. Results from six IBD surveillance sites in Mongolia
howed low rates of etiologic diagnosis and illustrated the
hallenges experienced regionally in surveillance [14]. Unlike
urveillance for measles and acute ﬂaccid paralysis (AFP) for polio,
onducting high quality facility-based surveillance of pneumo-
occi required signiﬁcant cooperation from clinicians, application
f standardized case deﬁnition, as well as the implementation
f specimen collection protocols and advanced laboratory tech-
iques. To address some of the challenges, annual trainings on
urveillance procedures were held for nurses and doctors, con-
ultations were conducted to ensure compatibility between the
urveillance case deﬁnition of pneumonia and the deﬁnition in Inte-
rated Management of Childhood Illness (IMCI) guidelines, and the
requency of pneumococcal disease reporting was  increased from
he standard of twice per year to monthly. Despite some improve-
ents, Dr. Surenkhand reported that the high rate of pre-hospital
ntibiotic use was a formidable barrier affecting laboratory testing
nd IBD surveillance in Mongolia. As of March 2015, Mongolia, a
avi-graduating country was approved to receive support through
dvance market commitment for PCV introduction in 2016 [15].
With the introduction of PCV in countries in the region, panel
articipants concluded there was potential to leverage existing
urveillance systems for important post-introduction impact eval-
ation studies and routine surveillance, however, in order to do so,
ountries would need to take ownership, and exert political pres-
ure in order to enhance resources to support the establishment
f additional surveillance sites as needed and strengthen existing
ystems.
. Spotlight on pneumococcal conjugate vaccines
Dr. Rajesh Kumar provided an overview of the history, develop-
ent, and efﬁcacy of pneumococcal vaccines with a speciﬁc focus
n PCVs, which is still currently under consideration for introduc-
ion in India. At the time, both PCV10 and PCV13 were licensed
nd available in the Indian private sector [16], but remained unaf-
ordable to the masses and will continue to do so until the vaccine
s introduced in the Indian National Immunization Schedule. Find-
ngs from a study reported that the high cost of PCV remained a
ajor barrier for patients and limited access despite doctors’ rec-
mmendations to vaccinate [17]. To date, PCV has not been used
n the public sector and also to our knowledge there is limited use
f PCV in private sector with no reported coverage data in India.
ecause India has the highest number of pneumonia deaths in the
orld with pneumonia contributing to approximately 32% of the
eaths in the 1–59 months age group in India1 [18], experts agreed
hat vaccines against pneumococci should be an integral part of a
omprehensive approach to prevent pneumonia and reduce related
hild morbidity and mortality.
The available data estimates PCV efﬁcacy at 80% (95%CI 58–90%)
or vaccine serotypes, 58% for all serotypes, 27% for radiological
neumonia and 6% for clinical pneumonia [19]; Dr. Kumar sug-
ested that India will need to leverage better diagnostic tools to
onitor pneumococcal disease burden and conduct efﬁcacy trialsor PCV10 and PCV13 in order to mobilize a decision of vaccine
ype. Given available data indicating acceptable safety proﬁles of
he vaccines and additional protective beneﬁts of the vaccination
e.g., reduction in hospitalizations and potential to prevent deaths)
1 Calculated using data from Liu et al. (2012). (2016) 2622–2626
[16], there was  a strong consensus to consider the introduction of
PCV in the National Immunization Schedule in India and enhance
surveillance of the pneumococci serotypes pre- and post-vaccine
introduction. One study also reported high coverage of PCV would
result in signiﬁcant cost savings to both the public and private sec-
tors, especially in high mortality states such as Bihar, which face
some of the highest burden of disease [20].
Dr. Cynthia Whitney presented evidence on the indirect effects
of PCV. Indirect effects also known as herd immunity, refers to
the reduction of pneumococcal disease in unvaccinated individ-
uals who  live in the same communities as vaccinated individuals.
One study conducted in United States after the introduction of the
heptavalent PCV (PCV7) in 2003 reported a higher (94%) reduction
in vaccine type disease in children <5 years of age than expected
(64%) based on the PCV coverage [21]. Indirect protective effects
of PCV7 were also reported consistently across different popula-
tions in high income countries with vaccine coverage as low as
40% [22,23]. Recently published data from studies in Kiliﬁ, Kenya
presented by Dr. Laura Hammitt at the symposium demonstrated
two thirds decrease in nasopharyngeal carriage with vaccine type
strains of S. pneumoniae in individuals of all age groups following
programmatic use of PCV10 [24]. Other publications from Gambia
and South Africa supported this ﬁnding [25,26].
Though the magnitude and rate at which these indirect effects
develop depend on vaccination coverage and proportion of disease
caused by vaccine serotypes, evidence presented at the symposium
indicated that indirect protective effects of vaccination resulted in
disease reductions across unvaccinated age groups in both high-
and low-income country settings. Therefore, experts agreed that
indirect effects will likely be seen in Asian countries as the vaccine is
introduced after 40–50% of the population is immunized. They also
recommended for policymakers to factor in the beneﬁts of indirect
effects into cost effectiveness estimates and other analyses used
in informing policy decisions concerning PCV introduction [22,27].
Findings form one study in the United States, which incorporated
the indirect effects of PCV7, demonstrated that the vaccine is not
only cost effective but also leads to signiﬁcant cost-savings [27].
Dr. Samir Saha also presented data on the potential role of PCVs
in reducing the prevalence and spread of antibiotic resistant strains
of pneumococci. The vaccines contain most of the serotypes asso-
ciated with drug resistance, and studies reported that PCV use
was associated with reduction in these strains in both the vacci-
nated and unvaccinated population [28]. There was  also evidence
that extensive use of PCV decreased the emergence of antibiotic
resistant strains in the community by reducing antibiotic use [29].
While the possibility of serotype replacement with strains that
could potentially become prone to drug resistance was  raised, to
date, no data has reported such a phenomenon [30]. Dr. Saha also
highlighted the importance of post introduction surveillance, par-
ticularly in the context of monitoring serotype replacement and
antibiotic sensitivity to guide the selection of future PCV vaccine
candidates [30].
4. Regional experiences with the introduction of
pneumococcal conjugate vaccines
In the ﬁnal panel, experts shared their unique country-speciﬁc
experiences relating to PCV introduction, presenting on various
topics ranging from epidemiological data to policy-making and
program implementation.
In October 2012, Pakistan became the ﬁrst South Asian country
to introduce PCV10 with Gavi support [31]. Dr. Asad Ali presented
ﬁndings from the surveillance of pneumococcal meningitis among
children in the Sindh province prior to PCV introduction, which was
conducted with Gavi support. The study found a low rate of direct
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etection of S. pneumoniae but adjustments for case recruitment
nd diagnostic sensitivity showed Pakistan had rates of pneumo-
occal meningitis similar to those seen in higher income countries
n the pre-vaccine era [32]. He also presented the objectives of the
CV10 evaluation study, which will assess the impact of PCV on IPD
nd nasopharyngeal carriage [33]. In addition, a Gavi-sponsored
tudy of the impact of PCV 10 in Sindh (Pakistan) is ongoing with
 focus on determining coverage rates and evaluating efforts to
mprove coverage in selected districts. Findings of the latter studies
ill be published in 2016 [33].
Dr. Eric Tayag presented the experiences of PCV10 introduction
n 2013 in the Philippines [34], a non-Gavi country. Pneumonia was
he leading cause of death among children under ﬁve years of age
n 2010 and 2011. Professional organizations and advocacy groups,
uch as, the Philippine Foundation for Vaccination championed for
CV introduction particularly in the context of achieving MDGs and
niversal Health Coverage. Due to the high vaccine price ($55 per
hild), the vaccine was introduced in a phased manner. Initially
nly 300,000 eligible infants in two regions with high burden of
llness were targeted for vaccination with PCV 10 in 2013 and plans
ere made to vaccinate another cohort of 300,000 eligible children
n four regions facing a high burden of disease in 2014. In 2014,
CV13 was selected based on a WHO  Western Paciﬁc Region study,
hich concluded that PCV 13 had higher cost–effectiveness when
ompared to PCV10.
The Philippines addressed several barriers and created an
nabling environment for PCV introduction by strengthening IPD
urveillance, designing impact studies at low cost, and demonstrat-
ng the beneﬁts of vaccines [34]. They also accessed vaccines from
heaper markets and engaged development and advocacy partners
n order to continue efforts to improve child health and survival
34].
Dr. Anonh Xeuatvongsa reported on the phased introduction
f PCV13 in Lao PDR in 2013 [35,36]. The national government
ecognized that respiratory infections were the leading cause of
orbidity and mortality among children under ﬁve years of age
n Lao PDR. Rural communities in particular had poor access to
ntibiotics and demand for an effective vaccine was  high, espe-
ially among parents who had seen their children suffer from the
ymptoms. Though the only data available from a major urban hos-
ital showed low IPD rates as diagnosed by culture, evidence from
tudies that incorporated more advanced diagnostic techniques
emonstrated higher burdens of pneumococcal disease in Asia sim-
lar to pre-vaccine global rates. There was strong consensus among
ecision-makers that pneumococci contributed to a large portion of
evere pneumonia and was a major cause of child illness and death.
urthermore, efﬁcacy and the beneﬁts of PCV impact, which had
een sufﬁciently demonstrated globally, solidiﬁed Lao PDR’s deci-
ion to introduce the PCV into the national immunization program.
he vaccine was introduced in the capital Vientiane and Vientiane
rovince with Gavi support in 2013 and at the time, a tentative
ationwide roll-out was  planned for 2014. Now, Lao PDR faces the
hallenge of measuring PCV impact since accurate baseline data
re not available [36]. The country is collaborating with interna-
ional academic centers and development partners to support such
valuation studies.
. Call to action for the introduction of PCV and concluding
emarks
Based on the wealth of data presented demonstrating the evi-
ence of the burden of disease and the positive impact of PCV, the
ymposium concluded that countries should prioritize introducing
CV through national immunization programs as an integral part
f a comprehensive strategy to prevent pneumonia and improve (2016) 2622–2626 2625
child health. Emphasis was placed on India where PCV introduction
is expected to not only lower the incidence of pneumonia but also
address the substantial burden of invasive pneumococcal disease.
Data on PCV effectiveness in LMICs in Asia and Africa also demon-
strated the potential for PCV to have a large impact in reducing
deaths and hospitalization among the poorest children who  face
the highest risk of disease and death. At the same, the symposium
delegates acknowledged that critical gaps exist for implementing
an effective PCV introduction and evaluation program. These lim-
itations range from diagnostic challenges of estimating disease
burden, availability of well performing surveillance sites and health
system barriers which can severely affect vaccine delivery and
the ability to conduct impact evaluation. With country-level lead-
ership, adoption of new diagnostic techniques, the expansion of
laboratory surveillance and strengthening of health systems capac-
ity, the introduction of PCV will provide an essential tool to reduce
child mortality accelerate the gains in child survival for the region.
The symposium participants made a strong plea to all countries in
Asia to make the introduction of PCV a top priority in their respec-
tive countries in order to save countless lives in the next decade.
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